Asia-Pacific Glycomics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Enzymes, Instruments, Kits, and Reagents), Application (Drug Discovery and Development, Diagnostics, Immunology, Cancer, and Others), and End User (Pharma

Asia-Pacific Glycomics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Enzymes, Instruments, Kits, and Reagents), Application (Drug Discovery and Development, Diagnostics, Immunology, Cancer, and Others), and End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Contract Research Organizations)

The APAC glycomics market is expected to grow from US$ 320.16 million in 2022 to US$ 699.78 million by 2028; it is estimated to grow at a CAGR of 13.9% from 2022 to 2028.
By enhancing the characterization of molecules crucial to the development of diseases, glycomics has the potential to pave the way for innovative treatment approaches. It can be a substantial addition to technologies used in genomes and proteomics. Comparative glycomics will be essential for identifying the glycans that cause disease, and studies will provide light on the relationship between clinical outcomes and glycomic anomalies. Immunohistochemistry (IHC), Liquid Chromatography-Mass Spectrometry (LC-MS), and high-throughput fluorescence flow cytometry have long been used to distinguish cell populations using glycoproteins. These are the important technologies utilized to advance glycomics. By separating several glycoprotein isoforms from a single protein species, LC-MS can provide structural details about glycoconjugates. Unbiased surveys of cellular proteomes are now available due to high-throughput MS-based proteomics, and the method is swiftly applied to glycomics. Structural reference databases are quickly emerging to close the gap between the variety and complexity of glycan structures. Identification of disease-related glycoconjugates by LC-MS, which employs antibody-based capture to view glycoconjugate expression with cell-staining or fluorescence, can be used to further assess or validate IHC. Targeting complete cells rather than tissue fragments, immunocytochemistry (ICC) reveals glycoprotein expression patterns at the cellular level utilizing the same imaging techniques as IHC. It will be possible to see new aspects of glycomics, such as a more thorough characterization of metabolic junctions and pathways, by modifying IHC and ICC to concentrate on additional glycoconjugates, such as glycolipids. Tandem or multi-technology procedures, such as MS-IHC, will provide labs with more analytical ability to handle the complexity of glycoconjugates and improve glycoconjugate diagnosis. The clinical applications of glycomics are catching up to those of genomics and proteomics due to the development of new high-throughput methods to study the structure and expression of glycans and ongoing innovation in glycan biomarkers and therapies. Integrating glycomics will revolutionize precision medicine into an extensive omics strategy, providing new information on the interactions between genes, proteins, and glycans. The combination of omics data with digital health platforms has the potential to improve clinical trials and aid in the creation of more complex knowledge of illness among researchers and doctors. Although these and other scientific discoveries are making their way from the lab to the clinic, widespread acceptance of glycomics and personalized medicine will necessitate significant changes in regulatory and reimbursement procedures and legislative privacy laws. Thus, customized healthcare challenges will be met and overcome with the assurance that the research behind glycomic medicine is decent and that the practice of medicine that it informs is evidence-based. So, new tools in glycomics research are expected to drive the market in the coming years.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the APAC glycomics market. The APAC glycomics market is expected to grow at a good CAGR during the forecast period.
APAC Glycomics Market Revenue and Forecast to 2028 (US$ Million)

APAC Glycomics Market Segmentation

The APAC glycomics market is segmented based on product, application, end user, and country. Based on product, the APAC glycomics market is segmented into enzymes, instruments, kits, and reagents. The enzymes segment dominated the market in 2022. The enzymes segment is further segmented into glycosidases, glycosyl transferases, sialyltransferases, neuraminidases, and others. The instruments segment is also segmented into mass spectrometers, MALDI-TOF, HPLC, lectin arrays, antibody arrays, and others. The kits segment is categorized into glycan release kits, glycan labeling kits, glycan purification kits, and others. The reagents segment is segmented into oligosaccharides, monosaccharides, glycoproteins, and others.
In terms of application, the APAC glycomics market is segmented into drug discovery and development, diagnostics, immunology, cancer, and others. The drug discovery and development segment dominated the market in 2022. Based on end user, the APAC glycomics market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and contract research organizations. The pharmaceutical & biotechnology companies segment dominated the market in 2022. Based on country, the APAC glycomics market has been categorized into China, India, Japan, South Korea, Australia, and the Rest of APAC. China dominated the market in 2022.
Agilent Technologies, Inc.; Bruker Corporation; MERCK KGaA; New England Biolabs; S-BIO (Sumitomo Bakelite Co., Ltd.); Shimadzu Corporation; Takara Bio Inc.; Thermo Fisher Scientific Inc.; and Waters Corporation are among the leading companies in the APAC glycomics market.

Reasons to buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the APAC glycomics market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the APAC glycomics market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth APAC market trends and outlook coupled with the factors driving the glycomics market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution